FIG. 2.

(A) Alignment of all protease sequences used in this study. All sequences include NC/p1 and p1/p6 cleavage site sequences except for WT, the synthetic wild-type variant. Mutations associated with protease inhibitor resistance are shown against a green background; polymorphic mutations are shown against a blue background. The Q7K mutation in WT, highlighted in gray, was engineered to stabilize the protease to autoproteolysis. (B) In vivo exposure to protease inhibitors and phenotypic resistance profiles are shown for the drug-resistant protease panel. Inhibitor susceptibilities are expressed as 50% inhibitory concentrations relative to that of a reference control.